STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #332 by analyst upside · 2026-06-27
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Healthcare · Market Cap $162M · P/E 0x
ANALYST PRICE TARGET
+303.9%
implied upside to consensus target
Current Price $8.74
Consensus Target $35.3
Bull Target $52.0
Bear Target $17.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
0
Sell
0
52-Week Low $6.72
52-Week High $20.56
YTD Return +11.1%
FUNDAMENTALS
Market Cap $162M
P/E Ratio (TTM) N/A
Forward P/E -1.7x
EPS (TTM) $-5.74
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.72
52-Week High $20.56
Current Price $8.74
Bear Target $17.0
Bull Target $52.0
● Now $8.74 ● Target $35.3
TRADING DATA
Avg Volume 438K
YTD Return +11.1%
Analyst Count 10
Consensus Buy
Upside to Target +303.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is currently trading at $8.74 with a Wall Street consensus price target of $35.3, implying potential upside of 303.9% over the next 12 months. 10 analysts currently cover CRBP, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $52.0, while the most cautious has a target of $17.0.

CRBP operates in the Healthcare sector with a market capitalisation of $162M. The stock is up 11.1% year-to-date and is currently trading near the lower end of its 52-week range of $6.72 – $20.56.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CRBP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer — Reiterated
Outperform → Outperform 2026-06-17 14% win rate (7 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-05-27 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-05-26 31% win rate (48 calls)
Mizuho — Reiterated
Outperform → Outperform 2026-05-22 Building track record
Jefferies — Reiterated
Buy → Buy 2026-05-13 50% win rate (6 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-05-13 14% win rate (7 calls)
Guggenheim reit
Buy → Buy 2026-05-13 62% win rate (8 calls)
Guggenheim ● Initiated
Buy 2026-04-29 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →